These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8230098)

  • 21. Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.
    Scholz D; Billich A; Charpiot B; Ettmayer P; Lehr P; Rosenwirth B; Schreiner E; Gstach H
    J Med Chem; 1994 Sep; 37(19):3079-89. PubMed ID: 7932531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.
    Blundell TL; Lapatto R; Wilderspin AF; Hemmings AM; Hobart PM; Danley DE; Whittle PJ
    Trends Biochem Sci; 1990 Nov; 15(11):425-30. PubMed ID: 2278102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
    Smith AB; Cantin LD; Pasternak A; Guise-Zawacki L; Yao W; Charnley AK; Barbosa J; Sprengeler PA; Hirschmann R; Munshi S; Olsen DB; Schleif WA; Kuo LC
    J Med Chem; 2003 May; 46(10):1831-44. PubMed ID: 12723947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
    Randolph JT; Huang PP; Flosi WJ; DeGoey D; Klein LL; Yeung CM; Flentge C; Sun M; Zhao C; Dekhtyar T; Mo H; Colletti L; Kati W; Marsh KC; Molla A; Kempf DJ
    Bioorg Med Chem; 2006 Jun; 14(12):4035-46. PubMed ID: 16504523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A modular approach to HIV-1 proteinase inhibitor design.
    Uhlíková T; Konvalinka J; Pichová I; Soucek M; Kräusslich HG; Vondrásek J
    Biochem Biophys Res Commun; 1996 May; 222(1):38-43. PubMed ID: 8630071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Kiso Y; Mitsuya H; Erickson JW
    Adv Exp Med Biol; 1995; 362():445-9. PubMed ID: 8540355
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibitors of the protease from human immunodeficiency virus: synthesis, enzyme inhibition, and antiviral activity of a series of compounds containing the dihydroxyethylene transition-state isostere.
    Thaisrivongs S; Turner SR; Strohbach JW; TenBrink RE; Tarpley WG; McQuade TJ; Heinrikson RL; Tomasselli AG; Hui JO; Howe WJ
    J Med Chem; 1993 Apr; 36(8):941-52. PubMed ID: 8478908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of orally bioavailable, symmetry-based inhibitors of HIV protease.
    Kempf DJ; Marsh KC; Fino LC; Bryant P; Craig-Kennard A; Sham HL; Zhao C; Vasavanonda S; Kohlbrenner WE; Wideburg NE
    Bioorg Med Chem; 1994 Sep; 2(9):847-58. PubMed ID: 7712122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
    Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
    J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization.
    Billich A; Charpiot B; Fricker G; Gstach H; Lehr P; Peichl P; Scholz D; Rosenwirth B
    Antiviral Res; 1994 Dec; 25(3-4):215-33. PubMed ID: 7710270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.